Group items tagged

The General Pharmaceutical Council (GPhC) has produced a new resource to support pharmacists and pharmacy technicians who are providing pharmacy services to children and young people with gender incongruence or dysphoria. It emphasises that pharmacy teams providing such services need to adhere to the standard process of clinical assessment and care provision they have been trained to take as healthcare professionals. The starting point is that pharmacy professionals must provide compassionate, inclusive and person-centred care, within the current relevant legal and regulatory context. "It's essential that all patients have access to appropriate, high-quality and respectful healthcare, free from discrimination or bias," the GPhC noted

Powerchairs are generally four-wheeled or six-wheeled and non-folding, however some folding designs exist and other designs may have some ability to partially dismantle for transit. Four general styles of powerchair drive systems exist: front, centre or rear wheel drive and all-wheel drive. Powered wheels are typically somewhat larger than the trailing/castoring wheels, while castoring wheels are typically larger than the castors on a manual chair. Centre wheel drive powerchairs have castors at both front and rear for a six-wheel layout. Angel Wheelchair Electric standing wheelchair Standing up, driving function by power. Head and signal light (controlled by joystick). Adjustable headrest. Adjustable footplate. Detachable backrest Rigid steel framework W/liquid coating Flip-backward armrest Max speed: 9.15KM/H Front castor: 2.80/2.50-4 pneumatic castor (9") Rear wheels: 3.00-8 pneumatic tire (14") Available seat width: A (46 cm), D (42 cm) Max loading: A size: 135 kg Net weight w/o battery: 62.7 kg A powerchairs is a wheelchair that is propelled by means of an electric motor rather than manual power. Power wheelchairs are useful for those unable to propel a manual wheelchair or who may need to use a wheelchair for distances or over terrain which would be fatiguing in a manual wheelchair. They may also be used not just by people with 'traditional' mobility impairments, but also by people with cardiovascular and fatigue based condition. An powerwheelchair powers more than just chair. It gives the power to safely travel long distances on own. It empowers to navigate through home, backyard, school, workplace or local park. It gives power to do the things,want to do. It gives power. When accidents occur that leave permanent leg injuries, or as age sets in and joint pain becomes unbearable, the power chair acts as a gateway to continue living life to the fullest. The powerwheelchairs in our lineup are all battery powered, yet each device fills

Karma Ergo Lite 2501 Wheelchair The extremely lightweight Ergo Lite 2501 Transport Wheelchair weighs only 8.16 kg. and features an ergonomically-designed seat and backrest, making it one of the most comfortable transport chairs on the market. The folding seat and backrest make the S-Ergo ideal for storage or travel, and the built in AEGIS anti-bacterial cushion provides added comfort and support. Despite its light weight, the S-Ergo features a 115 kg. weight capacity along with large, 14" flat-free polyurethane rear tires. Karma Ergo Lite 2501 Wheelchair Features Lightest transporter on the market! Patented S-Style Ergonomic Seat Frame 6061 T-6 Aircraft-grade Aluminum Only 18 lb . (w/ footrests) Built in Silver Aegis Anti-bacterial Cushion Fixed Armrests w/Concaved Armpads Pocket Behind Backrest & Small Carry Pouch on Each Armrest 6" x 1" Polyurethane Front Casters 16" x 17" or 18" x 17" Seat Width S-Style Ergonomic Seat 14" Rear Polyurethane, High Tread, Flat Free Wheels 3-Stage handle brake: allows light to firm grip for lock Folding Backrest/ Folding Seat for Transporting in Vehicle or Travel Fixed Footrests w/ Extra Wide Footplates Frame Color: Pearl Silver Weight Capacity of 100 kg Ergonomic Transporter w/ handle brakes Karma Ergo Lite 2501 Wheelchair Measurements Seat Width 16 inch., 18 inch. Seat Depth 17 inch. Armrest Height 8 inch. Seat Height 19 inch. Back Height 17 inch. Overall Height 36 inch. Overall Open Width 23 inch., 25 inch. Folded Width 12 inch. Overall Length 39 inch. Weight Without Riggings 8 kg. Weight Cap 100 kg. Shipping Dimensions 35" L x 30" H x 12" W

An off licence has had its licence suspended after a team from Ealing Council found unmarked illegal items on the premises. Harcharan Singh claimed he was allowing locals to store their medicines at his shop, King Quality Foods, while they visited the nearby temple. Singh's representative, Surendra Panchal, told the panel about the reasons which baffled the chair of the licensing sub-committee, Cllr Anthony Kelly. Cllr Kelly did not comprehend how a package of drugs would be difficult to fit in someone's bag, pocket, or car. The officials found drugs including high blood pressure and diabetes medication at the store.

Veoza, a non-hormonal treatment for menopause, has been made available on the high street for the first time in the UK. British pharmacy chain Superdrug on Thursday (1st February) announced the launch of the newly approved menopause medication, expanding its comprehensive portfolio of products and services to support menopausal women. Veoza is a prescription medication that is used to manage vasomotor symptoms, specifically hot flushes and night sweats, which affect up to 80 per cent of women during menopause, as estimated by experts. It is recommended for women who prefer not to or are unable to take hormone replacement. Perimenopausal, menopausal and postmenopausal women, aged 45-65 who are not on Hormone Replacement Therapy (HRT) or hormonal contraception, and are suffering from moderate to severe vasomotor symptoms, are eligible to take the medication, the retailer said in a release.

The Royal Pharmaceutical Society (RPS) has released findings from its fifth annual workforce wellbeing survey, which was conducted in collaboration with the profession's charity, Pharmacist Support. Exposing the mental health challenges faced by pharmacists, the survey revealed a troubling statistic: 86 per cent of pharmacists are at a high risk of burnout. Inadequate staffing was the main factor contributing to burnout, followed by lack of work-life balance, insufficient protected learning time, absence of colleague or senior support, and long working hours. While pharmacies are encouraged to provide more clinical services, more than 60 per cent of pharmacists surveyed reported that they were not being offered "sufficient protected learning time" to focus on their professional development and learning needs. The survey also exposed a distressing trend of workplace abuse, with over 40 per cent of pharmacists reporting verbal abuse from the public, and 25 per cent from colleagues or managers.

Eating a diet higher in protein may help you pack on a better kind of pounds, according to a new study out today in the Journal of the American Medical Association.

Britain plans to launch a pilot programme exploring how new weekly weight-loss shots such as Novo Nordisk's Wegovy can be given to obese patients by general practitioners even as the drug's market launch remains unclear. The government's announcement on the £40 million pilot programme comes after drug cost-effectiveness watchdog NICE in March recommended the use of Wegovy in adults with at least one weight-related condition and a body mass index of 35, but only within the NHS specialist weight management scheme. The timing of Wegovy's launch in Britain - which would be only the fourth country to use it - is uncertain, however, after Novo last month rationed starter doses to secure supply to U.S. patients already on the regimen, after it was overwhelmed by demand there. British Prime Minister Rishi Sunak said on Wednesday (May 7) the pilot and fighting obesity-related diseases could reduce pressure on hospitals. It would also support "people to live healthier and longer lives, and helping to deliver on my priority to cut NHS waiting lists". The NHS endured a tough winter in England in particular, with waiting lists hitting record highs and staff striking for higher pay amid double-digit inflation.

Bristol-based Titan PMR, a technology firm specialising in PMR systems for community pharmacies, is set to roll out an innovative platform named 'Titanverse,' that it claims will redefine pharmacy management, offering comprehensive solutions extending beyond prescription management. This new platform takes a versatile approach, efficiently managing all facets of pharmacy operations, from high-level management down to daily tasks, according to top company officials. "Our aim is to reshape pharmacies into genuine health hubs, providing advanced services and harnessing state-of-the-art technologies," said Tariq Muhammad, CEO of Titan PMR. "Titanverse, our latest offering, is positioned to ignite this transformation, revolutionising clinical services in the same way its predecessor revolutionised dispensing. With Titanverse, we have the vehicle to drive this vision forward, placing pharmacies at the forefront of primary care in the future." Titanverse adopts a Teams approach, catering to pharmacies with multiple locations or specific focuses. It furnishes real-time analytics and employs a color-coded rating system for swift performance evaluation. Moreover, the platform eases operations by enabling task delegation, encompassing clinical checks and dispensing, all while backing private services with adaptable templates and workflows.

The NHS has secured a deal for 'Pembrolizumab' to treat women with triple-negative breast cancer. Up to 1,600 women a year affected by high risk triple-negative breast cancer are set to benefit from the confidential deal struck by the NHS and the Merck Sharp and Dohme's (MSD), manufacturer of Pembrolizumab. Triple-negative breast cancer affects around 8,000 women a year - accounting for 15% of all breast cancer cases. This will be the 25th breast cancer treatment fast-tracked to patients through funding from the Cancer Drugs Fund and the second treatment for triple negative breast cancer to be introduced this year on the NHS. NHS chief executive, Amanda Pritchard, said: "This is a hugely significant moment for women - the NHS has struck a new deal to roll out a potentially life-saving drug for patients suffering with the most aggressive form of breast cancer that has been traditionally very difficult to treat.

The Royal Pharmaceutical Society (RPS) and Pharmacist Support hosted a roundtable on the impact of pharmacy workforce wellbeing on patient safety on Wednesday (17 May). It also released its annual Workforce Wellbeing Survey which showed continued pressures on pharmacy teams. The discussion explored the actions needed to support staff so they can continue providing safe and effective patient care and included representatives from the NHS, professional bodies, employers, trade unions, education and regulators. A report of the roundtable will be published in the summer. Amandeep Doll, RPS Head of Professional Belonging, said: "We know that pharmacy teams go above and beyond for their patients, but are also under enormous pressure. "Now more than ever, we need to strive to make the pharmacy profession more inclusive and ensure that everyone's wellbeing is supported. "It is vital that we do all we can to encourage people into pharmacy and to support them so they can enhance their skills, develop their careers, and continue to deliver high-quality patient care. "This discussion was a welcome step and showed that making a difference for staff wellbeing requires a concerted effort from stakeholders across the whole of pharmacy.

To help stop the pharmacists pay delay in Northern Ireland, the Pharmacists' Defence Association (PDA) will present a motion on fairer pay to the ICTU Biennial Delegate Conference, taking place from 5 to 7 July. The PDA motion states, "…there are other employers within the health system, that echo Agenda for Change terms, despite the fact they are essentially private businesses contracted to the NHS, not actually public bodies. While echoing the pay structure has some advantages, these employers also seek to unnecessarily delay pay increases on the basis that the NHS changes are so delayed. The Universities in Ulster Schools of Pharmacy are ranked as some of the highest in the UK. They are gifting our population with high calibre graduates destined to provide excellent patient care. These pharmacists want to stay in a job that helps patients. They want to deliver the care that they have spent years of time and often thousands of pounds to render themselves confident and capable."

Winter pressures are already mounting on NHS staff ahead of December, with high levels of demand in hospitals due to a significant increase in cases of norovirus infection. Norovirus is a highly contagious virus which spreads through contaminated food, water or surfaces and causes vomiting and diarrhea. New NHS figures revealed that an average of 351 people were hospitalised with diarrhoea and vomiting symptoms every day last week in England, almost triple the number during the same period last winter, which was 126. The number of children in hospital with the virus was also higher last week (13) compared the same week last year (an average of just three), according to the weekly winter update published by the health service on 30 November.

The Federation of Small Businesses (FSB) on Thursday (4 December) announced a new strategic partnership with the Bank of England to protect small businesses from the risks associated with accepting counterfeit banknotes. Cash is still the number one customer payment method for 25 per cent of small high street businesses, and cash payments are expected to increase during the festive period, according to FSB. By becoming a Strategic Partner of the Bank of England's Banknote Checking Scheme, the organisation is trying to help its members become aware of the use of counterfeit notes, which has reputational and financial impacts. The FSB is encouraging its members to sign up to the Scheme, which offers training materials to staff so they can identify a counterfeit note at point of sale and know what to do with it, as well as stay up to date with best practice and bank note developments.

The Department of Health and Social Care (DHSC) announced that free COVID-19 lateral flow tests will be supplied through community pharmacies for at-risk groups. The service will operate from 6 November for patients aged over 12 years who are at risk of developing severe COVID-19 symptoms. Community pharmacies that have participated in this new initiative will be paid £4 plus VAT for each box of five lateral flow device test kits provided. Alastair Buxton, Director of NHS services at Community Pharmacy England said: "This is not going to be a high-volume service, but community pharmacy teams are well placed to provide LFD test kits to eligible patients with them having made over 25.5 million supplies of COVID-19 LFD test kits in 2021/22.

The Department of Health and Social Care has clarified that community pharmacists will not be among those allowed to issue sick notes, calling the service unsuitable to be provided over the counter. In response to a question from Pharmacy Business, a spokesperson for the department said that the policy change was "aimed at pharmacists working within general practices or hospital settings", adding: "The intention is that 'where' the fit note is issued will remain the same but 'who' issues it will change. The DHSC went on to explain that fit notes, known technically as 'Med3', were "not part of the NHS commissioned services" and therefore private providers, such as high street pharmacies, were unable to provide it under government provision. It added that since "fit notes should only be issued following a full assessment of a patient's fitness for work", it "would be an unsuitable service to be provided 'over the counter'.

A new, independent search engine has launched called Vitaminology which enables the search, discovery and comparison of vitamins and supplements to empower consumers to make more informed choices and find the right products for their personal health goals and requirements. The company has set out to reduce confusion in this market through choice and high-quality information as well as access to one-to-one consultations with accredited nutritional therapists. By offering the complete package of advice, resources and products Vitaminology helps people to lead healthier lives. Mike Murphy, who is chief nutritionist for Vitaminology, comments, "This innovative platform has a powerful comparison and filtering feature that helps to simplify the choices available for consumers so they can make better self-care decisions. This is supported by access to video consultations with nutritional therapists as well as a comprehensive library of ingredient profiles, articles clustered around health conditions and unique recipes to support wellness."

The Royal Pharmaceutical Society (RPS) has welcomed the appointment of Michael Matheson MSP as Cabinet Secretary for NHS Recovery, Health and Social Care in Scotland. Commenting on the announcement Laura Wilson, Director of RPS Scotland, said: "I would like to congratulate Michael Matheson on being appointed to this position. NHS recovery is vitally important, and pharmacy has a huge amount to offer this agenda. "Our current priorities include enabling pharmacists to take leadership of prescribing in all care settings, tackling health inequalities and advocating for change, implementing shared patient records between healthcare professionals to provide high-quality, person centred and safe patient care, improving pharmacists' wellbeing and tackling the climate emergency by encouraging sustainable and green prescribing across Scotland.

Leyla Hannbeck, chief executive of the Association of Independent Multiple Pharmacies has said pharmacists have been "struggling to obtain the very basic, most common cold and flu medicine." She told the PA news agency that the shortage wasn't around "just the branded medicines" but "also simple things like throat lozenges, cough mixtures or pain killers - particularly the ones that are soluble." Stating that the sector was finding it very difficult these shortages she said "those people who are in charge of supporting us with it are denying it." "The demand has been high because this season we've seen higher cases of colds and flu and people are obviously trying very hard to look after themselves and making sure that they use the relevant products to manage the symptoms.

Anglo-Swedish drugmaker AstraZeneca said on Monday (January 9) that it had struck a deal to buy US-based drug developer CinCor Pharma for up to $1.8 billion to increase its stock of heart and kidney drugs. Core to the deal is CinCor's experimental therapy baxdrostat, which is in development to treat conditions including high blood pressure and chronic kidney disease. AstraZeneca aims to combine baxdrostat with its own Farxiga, a diabetes drug whose sales ballooned after it was also shown to benefit patients with heart failure and kidney disease. Farxiga, whose sales jumped by almost 50 per cent during the first nine months of 2022 to reach $3.2 billion, belongs to a highly competitive class of drugs that includes rivals such as Boehringer Ingelheim and Eli Lilly's Jardiance. AstraZeneca gets about a third of its revenue from cancer drugs, but its heart, kidney and diabetes medicines are its second most lucrative business by sales, generating roughly $6.9 billion of the drugmaker's total revenue of more than $33 billion in the first three quarters of 2022.